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Objectives: Carotid artery stenting (CAS) has been recommended as an alternative to carotid endarterectomy (CEA) by
some clinicians. However, recently published clinical trials have reported 30-day stroke and death rates of 10% to 12%.
This prompted review of our experience with CAS in patients at high risk, to document our results and guide further use
of CAS.
Methods: From September 1996 to the present, we performed 114 consecutive CAS procedures in 105 patients.
Sixty-three patients were men (60%) and 42 patients were women (40%), with mean age of 70 years (range, 45-93 years).
Indications for CAS included recurrent stenosis after previous CEA in 74 patients (65%), primary lesions in 32 patients
at high risk (28%), and carotid stenosis with previous ipsilateral radiation therapy in 8 patients (7%). Asymptomatic
stenosis (>80%) was managed in 70 patients (61%), and symptomatic lesions (>50%) were treated in 44 patients (39%).
Results: CAS was technically successful in all patients. Mean severity of stenosis before CAS was 87% 6%, compared with
9% 4% after CAS. Two patients (1.9%) died, 1 of reperfusion–intracerebral hemorrhage and 1 of myocardial infarction
10 days after discharge; and 1 patient (0.95%) had a stroke (retinal infarction), for a 30-day stroke and death rate of
2.85%. Two patients (1.9%) had transient neurologic events. No cranial nerve deficits were noted. No neurologic
complications have been noted in the last 27 patients (26%).
Conclusions: A 30-day stroke and death rate of 2.85% in our experience demonstrates acceptability of CAS as an alternative
to repeat operation or primary CEA in patients at high risk or in patients with radiation-induced stenosis. We recommend
further clinical investigation of CAS and participation in clinical trials by vascular surgeons. (J Vasc Surg 2003;37:
1234-9.)
Carotid endarterectomy (CEA) is the currently recom-
mended standard for management of symptomatic1-3 and
asymptomatic4,5 high-grade extracranial carotid stenosis.
Carotid artery stenting (CAS) has emerged as a useful and
potentially less invasive alternative to CEA.6-11 Recently
published consensus statements12,13 have suggested that
CAS may be preferred in specific subgroups of stenotic
lesions, including carotid recurrent stenosis after previous
CEA, stenosis in patients at high risk with significant med-
ical comorbidity, anatomically inaccessible lesions above
C2, and radiation-induced stenosis. However, recent clini-
cal trial reports14,15 have documented 30-day stroke and
death rates of 10% to 12%, raising significant issues and
concerns regarding the safety of this new technique. To
address these reports, we reviewed our experience with
CAS in a cohort of patients at high risk, to document
short-term and long-term results and guide further treat-
ment with CAS.
METHODS
Patient population. From September 1996 to May
2002, 105 consecutive patients underwent 114 CAS pro-
cedures as part of an Institutional Review Board–approved
program. Informed consent was obtained, and information
was prospectively collected regarding symptomatic status,
degree of stenosis, characteristics of previous operations,
and presence of medical comorbidity.
Patients included in the program had symptomatic
(50% diameter) or asymptomatic (80%) carotid recur-
rent stenosis after previous CEA; symptomatic (50%) or
asymptomatic (80%) primary carotid stenosis with a his-
tory of radiation to the ipsilateral neck; and symptomatic
(50%) or asymptomatic (80%) primary carotid stenosis
with one or more medical comorbidity, including coronary
artery disease requiring angioplasty or bypass grafting
within the 6 months before carotid intervention, history of
congestive heart failure (CHF), current ejection fraction
less than 30%, steroid-dependent chronic obstructive pul-
monary disease, or measured forced expiratory volume in 1
second less than 30% of predicted.
CAS protocol. Patients were referred after history,
findings at physical examination, and results of duplex
ultrasound scanning confirmed eligibility for participation.
Pretreatment in all patients included aspirin, 325 mg/d,
and clopidogrel, 75 mg twice a day, for 2 days before the
procedure. Local anesthetic (1% lidocaine) was infiltrated at
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the access site. No sedation was given before or during the
procedure. Intra-arterial blood pressure and oxygen satu-
ration were monitored continuously, and neurologic status
was assessed at regular intervals. Weight-adjusted heparin
was administered (70 U/kg), and activated clotting time
was maintained at 250 to 300 seconds.
A description of our endovascular technique has been
published.10,11 Standard retrograde access was achieved
through the common femoral artery, or the left brachial
artery in 1 patient, with a 6F vascular sheath. A 0.035 inch
guide wire (Wholey modified J, 175 cm; Mallinkrodt, St
Louis, Mo) in a 5F cerebral diagnostic catheter (Vitek;
Cook, Bloomington, Ind) was introduced for selective
cannulation of the common carotid artery. Digital angiog-
raphy was performed in the lateral, anteroposterior, and
oblique planes to clarify severity of stenosis (Fig 1). Intra-
cerebral views were obtained to assess baseline cerebrovas-
cular anatomy. Subsequently, the diagnostic catheter was
exchanged over a 0.035 inch exchange-length (260 cm)
Amplatz Super Stiff guide wire (Meditech/Boston Scien-
tific, Natick, Mass) for an 8F or 6F 100 cm long sheath,
which was passed into the common carotid artery. Self-
expandable stents were used in all patients but 5, in whom
short balloon expandable stents were used early in our
experience. Stenoses were crossed with 0.018 inch Road-
runner extra-support guide wires (Cook) in patients in
whom the WallStent (Meditech/Boston Scientific, Minne-
apolis, Minn) was used, and 0.014 inch guide wires were
used in patients in whom the ACCULINK (Hi-Torque
Floppy; Guidant, Menlo Park, Calif) was used. In the last
26 patients, an anti-embolic distal filter device (ACCU-
NET; Guidant) was used (Fig 2).16 Pre-stent dilation was
performed in about 20% of cases with low-profile 3 to 4
30-mm balloon catheters inflated to 8 atm, followed by
stent deployment. Post-stent dilation was performed with 5
or 6 mm high-pressure balloons inflated to 8 atm in all
cases. On completion of the procedure, ipsilateral cervical
(Fig 3) and intracranial carotid angiography was performed
to assess technical success and to exclude distal cerebral
embolization.
Patients were transferred to a monitored intermediate
care facility and were discharged the next morning. A
post-procedure clinical examination and duplex ultrasound
scanning was performed before discharge to assess stent
patency and position. Clopidogrel was continued at 75
mg/d for 4 weeks, and aspirin was continued indefinitely.
Patients were followed up at 6-month intervals with clinical
examination and duplex ultrasound scanning. Technical
failure was defined as inability to access the lesion or post-
stenting residual stenosis 15% or greater. Transient isch-
emic attack (TIA) was defined as a focal hemispheric deficit
that resolved within 24 hours, whereas a similar deficit
lasting more than 24 hours was defined as a stroke. Amau-
rosis fugax was defined as focal retinal deficit lasting less
than 24 hours. Clinically significant in-stent recurrent ste-
nosis was defined as more than 80% reduction in diameter
as identified at duplex ultrasound scanning and confirmed
at angiography. A significant arterial access site complica-
tion was defined as any dissection, hematoma, pseudoan-
eurysm, arteriovenous fistula, or infection requiring blood
transfusion, intravenous antibiotic therapy, or surgical or
endovascular intervention.
RESULTS
Patient characteristics. Patient mean age was 70 years
(range, 45-93 years). Sixty percent of patients were men
(n  63), and 40% were women (n  42). Thirty-nine
percent of procedures were performed to treat symptomatic
primary carotid stenosis or carotid recurrent stenosis after
previous CEA (stroke, n  12; TIA, n  27; amaurosis
fugax, n 5), and 61% were performed for management of
Fig 1. Selective lateral carotid angiogram shows high-grade ste-
nosis in proximal internal carotid artery.
Fig 2. Selective angiogram shows results after placement of a
self-expandable nitinol stent. An antiembolic device (ACCUNET)
was used during the procedure.
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asymptomatic disease (no neurologic symptoms, n  62;
nonlateralizing “global” symptoms, eg, lightheadedness or
headache, n 8). Mean severity of stenosis treated was 87%
 6% (SD). Indications for CAS are presented in Table I,
and medical comorbidity are summarized in Table II.
RESULTS
All CAS procedures were accomplished successfully.
Self-expanding WallStents (8  20 mm and 10  20 mm)
were used in 81 CAS procedures (71%); self-expanding
ACCULINK stents (nickel-titanium, 8 to 6 mm or 10 to 7
mm tapered by 20 or 30 mm) were used in 28 instances
(24.6%); and 5 balloon-expandable stents were used during
the early part of our experience (4.4%).
No contrast extravasation, arterial disruption, or subin-
timal dissections were observed. Residual stenosis after
CAS did not exceed 15% in any case; mean residual stenosis
was 9%  4% (SD). Arterial access site hematoma or pseu-
do-aneurysm requiring blood transfusion or operative in-
tervention was observed in 5 patients (4.7%).
Overall 30-day stroke and death rate was 2.85%. Two
deaths occurred (1.9%), 1 from myocardial infarction 10
days after discharge in a patient with symptomatic stenosis
with medical comorbidity (1 of 32 [3.1%]) and 1 from
intracranial hemorrhage 1 day after CAS in a patient with
asymptomatic recurrent stenosis after CEA. Stroke, a reti-
nal infarction with partial field of vision loss, occurred in 1
patient (0.95%) with asymptomatic recurrent stenosis (2 of
74 [2.7%]). No complications occurred in symptomatic or
asymptomatic patients who had undergone radiation
therapy (0 of 8 [0%]). Minor neurologic events (TIA)
occurred in 2 patients (1.9%). Mean in-hospital stay was
1.6 days (range, 1-7 days) for the entire series; and 72%
of patients were discharged the morning after the proce-
dure.
All patients were followed up at 6-month intervals
(mean follow-up, 25.9 months; median follow-up, 22.4
months; range, 3.1-69 months). During this period, high-
grade in-stent recurrent stenosis with 80% or greater diam-
eter reduction developed in 4 patients (3.8%). Although
these patients had no symptoms, repeat intervention was
recommended because of severity of the recurrent stenosis.
In 3 of these patients treatment with angioplasty alone was
successful, whereas in 1 patient angioplasty with additional
stenting was required. Mean time to recurrent stenosis was
13 months (range, 6.8-21 months). All 4 patients have
remained asymptomatic without recurrent stenosis during
further follow-up.
Table II. Medical comorbidity in a consecutive series of
patients undergoing carotid artery stenting
Medical Comorbidity No. %
CAD 74 64.9
CAD with coronary intervention within
6 months before CAS
26 22.8
History of CHF or EF 30% 4 3.5







CAD, Coronary artery disease; CAS, carotid angioplasty stenting; CHF,
congestive heart failure; EF, left ventricular ejection fraction; COPD,
chronic obstructive pulmonary disease; FEV1, forced exhaled volume at 1
second.
Fig 3. Post-procedure photograph of the anti-embolic device (ACCUNET) used in the patient in Fig 2. Note debris
(arrow) trapped within the device.
Table I. Indications for carotid angioplasty stenting in a
consecutive series of 105 patients
Indication No. %
Carotid recurrent stenosis after previous
carotid endarterectomy
74 64.9
Primary carotid stenosis in patients with severe
medical comorbidity
32 28.1
Carotid stenosis with previous ipsilateral
cervical radiation therapy
8 7
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DISCUSSION
Results from two randomized clinical trials comparing
CAS with CEA have reported 30-day stroke and death rates
in the 10% to 12% range. In a trial that was stopped early by
the sponsor, Alberts14 presented data comparing CEA with
CAS in 219 patients with symptomatic carotid stenosis in
the range of 60% to 99%. No risk stratification was at-
tempted, and the cohort comprised a mix of patients eligi-
ble and ineligible for the North American Symptomatic
Carotid Endarterectomy Trial (NASCET). All patients in
the CAS group received a WallStent endoprosthesis, as well
as aspirin and ticlopidine periprocedurally. The 30-day
periprocedural stroke and death rate was 12.1% for CAS
and 4.5% for CEA (P .049). The 1-year ipsilateral stroke
rate was 3.6% in the operative group, compared with 12.2%
in the stent group (P  .022). The reliability of results in
this study was limited by the observations that complica-
tions were clustered around inexperienced operators and
that the number of patients was small.
The recently published Carotid and Vertebral Artery
Transluminal Angioplasty Study (CAVATAS) multicenter
trial15 randomized 504 patients with carotid artery steno-
sis, of which most had symptoms (96%), to undergo either
balloon angioplasty or CEA. Patients were not stratified
according to medical comorbidity or cause of stenosis;
therefore this cohort also contained patients with minimal
or absent medical comorbidity and those who would have
been considered eligible for NASCET. Of note, stenting
was performed in only 26% of the 251 patients randomized
to the endovascular treatment arm. The authors of CAVA-
TAS acknowledged that the results of balloon angioplasty
would be out of date when their study was published,
because carotid stent placement has emerged in the past
few years as the preferred method. The 30-day disabling
stroke and death rate was 6.4% for endovascular manage-
ment and 5.9% for CEA, compared with 10.0% and 9.9%
for overall stroke and death. Cranial nerve palsy occurred in
8.7% of surgical patients, but in none in the endovascular
treatment group. While endovascular and surgical manage-
ment resulted in comparable complication rates, the com-
plication rate reported for the endovascular group was
higher than previously reported.6-11
This prompted review of our own data for a carefully
selected group of patients with carotid stenosis or recurrent
stenosis who would be considered at higher risk for periop-
erative neurologic or cardiac morbidity and mortality. In
this group of 105 patients, we performed 114 carotid
interventions, with a combined 30-day stroke and death
rate of 2.85%. This complication rate compares favorably
with the 30-day stroke and death rates noted after CEA by
our group10 and subsequently by randomized multicenter
trials.1-5 Our results are also similar to the 30-day stroke
and death rates for CAS in studies with a larger number of
patients that did not limit the procedure to high-risk
groups.9,17
We accomplished carotid revascularization in 114 con-
secutive procedures, with a technical success rate of 100%.
Mean residual stenosis immediately post-procedure was 9%
 4% (SD). This indicates technical feasibility of CAS once
appropriate training and experience with necessary catheter
and guide wire skills are obtained. Our mean follow-up was
25.9 months (median, 22.4 months), with the longest
follow-up more than 5 years. An in-stent recurrent stenosis
rate of 3.8% over this long follow-up confirms that the
procedure is durable. The recurrence rate was low even
when most patients (67%) reviewed had post-CEA intimal
hyperplastic recurrent stenotic disease. Initial concerns
were raised that CAS may produce the high recurrence rates
of 16% to 59% observed in the coronary interventional
experience.19-21 A report of 8 CAS procedures performed
because of recurrent stenosis after CEA suggested a simi-
larly high in-stent recurrent stenosis rate.18 However, sig-
nificantly larger clinical series, including the present study
and others,22,23 confirmed in-stent recurrent stenosis rates
after CAS of less than 5%.
Seven percent of patients in this series had previously
received cervical radiation. These stenoses are frequently
long, multiple, or located in surgically less accessible loca-
tions. CEA through irradiated tissue historically has been
associated with increased perioperative morbidity and mor-
tality, including cranial nerve palsy.13 Radiation-induced
carotid stenosis has been identified as a high-risk group at
the Montefiore Consensus conference.13 CAS was recom-
mended as an appropriate alternative to CEA at that meet-
ing. We have used CAS preferentially to treat radiation-
induced carotid stenosis at our institution.
Carotid recurrent stenosis after CEA is uncommon and
is attributed to myointimal hyperplasia during the early
postoperative period (within 36 months) or recurrent ath-
erosclerosis thereafter. Hill et al24 reported absence of
operative morbidity and mortality in a series of 40 opera-
tions to treat recurrent stenosis after CEA. O’Donnell et
al25 reported a 4.2% 30-day stroke and death rate after
operative intervention in 48 patients with recurrent stenosis
after CEA. Transient cranial nerve palsy was observed in
18.9%, and 7.5% of the medically treated group experi-
enced a de novo stroke while being followed up medically
because of recurrent stenosis after CEA. The authors’ meta-
analysis of six other clinical series demonstrated an overall
30-day stroke and death of 5.2%. While the operative
complication rate in the series of O’Donnell and colleagues
was not significantly greater than that for primary CEA,
others report that repeat operation is associated with in-
creased risk for perioperative complications. In general, the
rate for neurologic events ranges from 4.3% to 19.5%, and
for cranial nerve palsy ranges from 9.2% to 19.8%.26-28
Because of these issues, several authors regard patients with
recurrent carotid stenosis as at high risk for repeat opera-
tion, as compared with primary CEA, and recommend CAS
as an alternative to operative management.6,10,11,29,30
Most patients (67%) in the current series underwent CAS to
treat recurrent stenosis after CEA. No cranial nerve palsies
were noted, and the overall periprocedural stroke and death
rate (2.85%) compares favorably with published data on
operative complications.
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Several authors have attempted to define higher risk for
primary carotid endarterectomy. McCrory et al31 analyzed
data for 1160 CEAs performed at 12 academic medical
centers and identified predictors of heightened risk. Overall
30-day stroke and death rate was 4.8%; however, predictors
of heightened risk included age older than 75 years, symp-
tomatic status (hemispheric TIA, non-disabling stroke),
diastolic blood pressure greater than 110 mm Hg, CEA
before planned aortocoronary bypass with history of an-
gina, evidence of intra-arterial thrombus, and stenosis near
the siphon (lesion above C2). Presence of two or more
predictors suggested a twofold increase in risk, which
would then approach 10%. Goldstein et al32 more recently
reviewed the same database and noted higher postoperative
stroke and death rates for women (5.6% vs 1.6%; P  .02),
for age older than 75 years (7.7% vs 1.8%; P .01), and for
history of CHF (8.1% vs 2.3%; P .03). Recently, Ouriel et
al33 identified a subset of patients at high-risk whose com-
posite end point of stroke, myocardial infarction, and death
was 7.4%, whereas the corresponding rate in a subset of
patients at low risk was 2.9% (P  .005). The subgroup at
high risk was identified by presence of coronary artery
disease, history of CHF, chronic obstructive lung disease,
or renal insufficiency. Finally, Rothwell et al34 analyzed
data for 1729 patients from the European Carotid Surgery
Trial who underwent CEA. They noted that risk for peri-
operative complications was higher in women, in cerebral
as opposed to ocular ischemia, in patients older than 75
years, in systolic hypertension, and in the presence of pe-
ripheral vascular disease. On the basis of these published
data, we identified a high-risk subset of patients with pri-
mary carotid stenosis with severe cardiac or pulmonary
disease. These patients formed a small subset of our overall
experience (28%) and were preferentially offered CAS.
Our results demonstrate that CAS can be performed
successfully once sufficient technical expertise is acquired.
Contrary to published reports,14,15 periprocedural compli-
cations were low and results were durable. Each institution
must make decisions regarding continued use of CAS on
the basis of their individual experience. However, for our
group, continued use of the technique in subsets of patients
considered at higher risk seems appropriate until data are
generated from larger randomized clinical trials and regis-
tries over the next 2 or 3 years.16
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